top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Advances and Novel Treatment Options in Metastatic Melanoma
Advances and Novel Treatment Options in Metastatic Melanoma
Autore Facchiano Antonio
Pubbl/distr/stampa Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Descrizione fisica 1 electronic resource (528 p.)
Soggetto topico Medicine
Soggetto non controllato melanoma
invasion
WNT5A
MARCKS
phosphorylation
MANS peptide
nanoparticles
cell therapy
tumor microenvironment
sex/gender
sex-hormones
immunity
microRNAs
immunotherapy
BRAF-mutant melanoma
BRAF inhibitor
mechanism of action
targeted therapy
tumour microenvironment
plasmacytoid dendritic cells
lactate dehydrogenase
TLR
interferon
CXCL10
TPC2
HIPPO
SOCE
metastasis
essential oils
angiogenesis
apoptosis
uveal melanoma (UM)
metastatic uveal melanoma (mUM)
prognostication
adjuvant therapy
metastatic therapy
metastatic dormancy
liver-directed-therapies
targeted-therapy
combined therapy
protein tyrosine phosphatase
PTPs inhibitors
melanoma immune infiltrate
BRAF inhibitors
microenvironment
resistance
therapy
therapeutic resistance
exosomes
extracellular vesicles
diagnosis
prognosis
ctDNA
liquid biopsy
prediction
patient stratification
BRAF
arthralgia
rheumatoid arthritis
carbonic anhydrase
hedgehog
cyclopamine
small molecules
acetazolamide
motility
metalloproteinases
FAK
cancer
mucosal melanoma
nivolumab
pembrolizumab
ipilimumab
radiotherapy
cholinergic system
acetylcholine
muscarinic receptors
nicotinic receptors
melanoma metastasis
ShcD adaptor protein
amoeboid motility
Rac1
DOCK4
melanoma PDX
target therapy
cancer stem cells
slow cycling phenotype
drug resistance
OXPHOS
lipid metabolism
cancer associated fibroblast
melanomagenesis
biomarkers
checkpoint inhibitor
PD-1
melanoma markers
cytokines
machine learning
Support Vector Machine
principal component analysis
BCL2L10
STAT3
cytotoxicity
survival
ABT-737
Bcl-2 family
ML258
HuR
MITF
metastases
siRNA
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910557612103321
Facchiano Antonio  
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Oncolytic Virus Immunotherapy
Oncolytic Virus Immunotherapy
Autore Marchini Antonio
Pubbl/distr/stampa Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Descrizione fisica 1 electronic resource (366 p.)
Soggetto topico Medicine
Clinical & internal medicine
Soggetto non controllato oncolytic viruses
melanoma
immunotherapy
checkpoint inhibitors
combinatory therapy
reovirus
oncolytic virus
adenovirus
oncolytic
virotherapy
targeting
immunogenic cell death
αvβ6 integrin
oncolytic adenovirus
cancer immunotherapy
multi-stage
immunostimulatory
arming
HSV-1
clinical trials
newcastle disease virus
NDV
cancer
immune checkpoint inhibitor
PD-1
PD-L1
CTLA-4
type I interferon
herpes simplex virus
retargeted virus
tropism retargeting
tumor
checkpoint inhibitor
vaccination
antigen-agnostic vaccination
HER2
parvovirus
tumor microenvironment
combination therapy
glioblastoma
pancreatic cancer
colorectal cancer
measles virus
vector engineering
immune checkpoint blockade
antitumor immune response
delivery
genetic modification
biomarkers
personalized oncolyticvirotherapy
class I HLA
immunosurveillance
immunoediting
oncogenic signaling
RAS
DNA methyltransferase inhibitor (DNMTi)
viral mimicry
epigenetic silencing
adoptive T cell therapy
CAR T cell
pancreatic ductal adenocarcinoma
vesicular stomatitis virus
small molecule
cancer immune therapy
cancer therapy
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910566462203321
Marchini Antonio  
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui